Trends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection

BACKGROUND: Treating anemia with erythropoietin (EPO) to hemoglobin (Hb) endpoints >11 g/dL may increase risk of serious adverse cardiovascular events. METHODS: We used medical records data (1996-2003 from the Adolescent Spectrum of HIV Disease Project [ASD] and 1996-2006 from the HIV Outpatient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Patrick S, Hanson, Debra L, Richardson, James T, Brooks, John T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257553/
https://www.ncbi.nlm.nih.gov/pubmed/22253666
http://dx.doi.org/10.2174/1874613601105010113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257553/
https://www.ncbi.nlm.nih.gov/pubmed/22253666
http://dx.doi.org/10.2174/1874613601105010113

Ejemplares similares